Total
0
Shares
Imugene (ASX:IMU) - CEO, Leslie Chong
CEO, Leslie Chong
Source: Imugene
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Imugene (IMU) will present its immunotherapy programme at the American Association for Cancer Research’s annual meeting
  • Imugene’s Chief Medical Officer is set to present at the meeting on the company’s HER-Vaxx cancer immunotherapy programme
  • HER-vaxx has shown promising antibody responses against HER-2 cancer growth signals in phase one and two preclinical trials
  • At this stage, the full content of the presentation is embargoed but will be made available when the presentation takes place in April
  • Imugene is up 5 per cent on the market, trading at 10.5 cents per share

Imugene (IMU) will present its immunotherapy programme at the American Association for Cancer Research’s annual meeting.

Imugene’s Chief Medical Officer, Dr Rita Laeufle, is set to present at the American Association for Cancer Research’s virtual annual meeting, scheduled for April this year.

IMU says the exhibition covers its HER-Vaxx cancer immunotherapy program.

HER-Vaxx is designed to produce an antibody response against a cancer growth signal receptor protein called ‘HER-2’, which is found on the cell surface in ovarian, lung and pancreatic cancers.

The immunotherapy is constructed from several B cell epitopes derived from the extracellular domain of the HER-2/neu protein.

Pre-clinical studies in phase one and two stages have shown HER-Vaxx can stimulate a potent antibody response to HER-2/neu, a well-known cancer target.

While the full content of the presentation is embargoed until the start of the conference, it will be made available online once the meeting has started.

The American Association for Cancer Research is widely regarded as one of the largest and oldest cancer research bodies.

Imugene is up 5 per cent on the market, trading at 10.5 cents per share at 10:38 am AEDT.

IMU by the numbers
More From The Market Herald
APM (ASX:APM) - CEO, Michael Anghie

" APM Human Services (ASX:APM) expands, acquiring Lifecare

APM Human Services International (APM) has acquired physiotherapy and home care group Lifecare for $68 million.
Resonance Health (ASX:RHT)

" Resonance Health (ASX:RHT) submits LiverSmart to FDA

Resonance Health (RHT) has submitted its LiverSmart device to the Food and Drug Administration (FDA) for US regulatory clearance.
Dotz Nano (ASX:DTZ) - CEO, Gideon Shmuel

" Dotz Nano (ASX:DTZ) signs Malaysian distribution deal for COVID-19 tests

Dotz Nano (DTZ) has entered into a distribution agreement with ScienceVision to promote, sell and distribute its COVID-19 virus detection technology in Malaysia.
Kazia Therapeutics (ASX:KZA) - CEO, Dr James Garner

" Kazia Therapeutics (ASX:KZA) releases “positive” second-phase study results for brain cancer treatment

Kazia Therapeutics (KZA) has opened the trading day green after reporting positive final results from a second-phase clinical study of its paxalisib drug